Biocryst Pharmaceuticals (BCRX) Revenue (2010 - 2026)

Biocryst Pharmaceuticals has reported Revenue for 17 years, with the latest figure at $156.4 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 7.48% year-over-year to $156.4 million; the trailing twelve-month figure through Mar 2026 stood at $479.9 million (down 4.69% YoY), and the FY2025 full-year result was $874.8 million, up 94.1% from the prior year.
• Revenue for Q1 2026 stood at $156.4 million, up from $708000.0 in the prior quarter.
• The five-year high for Revenue was $163.4 million in Q2 2025, with the low at $708000.0 in Q4 2025.
• Historically, Revenue has averaged $98.7 million across 5 years, with a median of $92.8 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue surged 161.94% — and 2025, when it sank 99.46%.
• Biocryst Pharmaceuticals' Revenue stood at $79.5 million in 2022, then grew by 17.42% to $93.4 million in 2023, then jumped by 40.83% to $131.5 million in 2024, then slumped by 99.46% to $708000.0 in 2025, then surged by 21992.23% to $156.4 million in 2026.
• The last three Revenue figures came in at $156.4 million (Q1 2026), $708000.0 (Q4 2025), and $159.4 million (Q3 2025), per Business Quant data.